Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia

Journal of Clinical Lipidology

Volumn 11, Issue 3, 2017, Pages 725-732.e5

  Paquette, Martine ^a   Chong, Michael ^b   Thériault, Sébastien ^c   Dufour, Robert ^a,d   Paré, Guillaume ^b,e,f,g   Baass, Alexis ^a,h  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b HAMILTON GENERAL HOSPITAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h MCGILL UNIVERSITY   (Canada)

Author keywords

Cardiovascular disease; Familial hypercholesterolemia; Genetic risk score; HDL C; LDL C; Risk stratification; SNP; TG

Indexed keywords

DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPID;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA DETERMINATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYGENIC RISK SCORE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; GENETIC VARIATION; GENETICS; PHENOTYPE; RISK FACTOR;

ADULT; CARDIOVASCULAR DISEASES; FEMALE; GENETIC VARIATION; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; PHENOTYPE; PREVALENCE; RISK FACTORS;

EID: 85018714554     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2017.03.019     Document Type: Article

References (41)

1. 1 Goldstein, J.K., Hobbs, H.H., Brown, M.S., Familial hypercholesterolemia. Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., (eds.) The Metabolic & Molecular Bases of Inherited Disease, 8th ed., 2001, McGraw-Hill, New York, 2863–2913.
2. 2 Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34:45 (2013), 3478–3490a.
3. 3 Austin, M.A., Hutter, C.M., Zimmern, R.L., Humphries, S.E., Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 160:5 (2004), 407–420.
4. 4 Innerarity, T.L., Mahley, R.W., Weisgraber, K.H., et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 31:8 (1990), 1337–1349.
5. 5 Abifadel, M., Varret, M., Rabès, J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:2 (2003), 154–156.
6. 6 de Ferranti, S.D., Rodday, A.M., Mendelson, M.M., Wong, J.B., Leslie, L.K., Sheldrick, R.C., Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation 133:11 (2016), 1067–1072.
7. 7 Moorjani, S., Roy, M., Gagné, C., et al. Homozygous familial hypercholesterolemia among French Canadians in Québec Province. Arteriosclerosis 9:2 (1989), 211–216.
8. 8 Austin, M.A., Hutter, C.M., Zimmern, R.L., Humphries, S.E., Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 160:5 (2004), 421–429.
9. 9 Slack, J., Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 2:7635 (1969), 1380–1382.
10. 10 Stone, N.J., Levy, R.I., Fredrickson, D.S., Verter, J., Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 49:3 (1974), 476–488.
11. 11 Mortensen, M.B., Kulenovic, I., Klausen, I.C., Falk, E., Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: prevalence, risk factor burden, and impact on age at presentation. J Clin Lipidol 10:5 (2016), 1145–1152.e1.
12. 12 de Sauvage Nolting, P.R., Defesche, J.C., Buirma, R.J., Hutten, B.A., Lansberg, P.J., Kastelein, J.J., Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 253:2 (2003), 161–168.
13. 13 Allard, M.D., Saeedi, R., Yousefi, M., Frohlich, J., Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort. Lipids Health Dis, 13, 2014, 65.
14. 14 Besseling, J., Kindt, I., Hof, M., Kastelein, J.J., Hutten, B.A., Hovingh, G.K., Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis 233:1 (2014), 219–223.
15. 15 Sijbrands, E.J., Westendorp, R.G., Defesche, J.C., de Meier, P.H., Smelt, A.H., Kastelein, J.J., Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 322:7293 (2001), 1019–1023.
16. 16 Sharifi, M., Rakhit, R.D., Humphries, S.E., Nair, D., Cardiovascular risk stratification in familial hypercholesterolaemia. Heart 102:13 (2016), 1003–1008.
17. 17 Paquette, M., Dufour, D., Baass, A., The Montreal-FH-Score: a new score to predict cardiovascular events in familial hypercholesterolemia. J Clin Lipidol 11 (2017), 80–86.
18. 18 Saavedra, Y.G., Dufour, R., Davignon, J., Baass, A., PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study. Arterioscler Thromb Vasc Biol 34:12 (2014), 2700–2705.
19. 19 Saavedra, Y.G., Dufour, R., Baass, A., Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk. J Clin Lipidol 9:6 (2015), 786–793.e1.
20. 20 Bertolini, S., Pisciotta, L., Di Scala, L., et al. Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. Atherosclerosis 174:1 (2004), 57–65.
21. 21 McPherson, R., Genome-wide association studies of cardiovascular disease in European and non-European populations. Curr Genet Med Rep 2 (2014), 1–12.
22. 22 Nikpay, M., Goel, A., Won, H.H., et al. A comprehensive 1000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 47:10 (2015), 1121–1130.
23. 23 Smith, J.A., Ware, E.B., Middha, P., Beacher, L., Kardia, S.L., Current applications of genetic risk scores to cardiovascular outcomes and subclinical phenotypes. Curr Epidemiol Rep 2:3 (2015), 180–190.
24. 24 Committee NH and LI (U. S) LRCPLM. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis, Volume 1, 1974, National Heart and Lung Institute, National Institutes of Health, New York.
25. 25 Minnich, A., Roy, M., Chamberland, A., Lavigne, J., Davignon, J., New methods for rapid detection of low-density lipoprotein receptor and apolipoprotein B gene mutations causing familial hypercholesterolemia. Clin Biochem 28:3 (1995), 277–284.
26. 26 Delaneau, O., Zagury, J.F., Marchini, J., Improved whole-chromosome phasing for disease and population genetic studies. Nat Methods 10:1 (2013), 5–6.
27. 27 Willer, C.J., Schmidt, E.M., Sengupta, S., et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 45:11 (2013), 1274–1283.
28. 28 Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:7510 (2014), 421–427.
29. 29 Marenberg, M.E., Risch, N., Berkman, L.F., Floderus, B., de Faire, U., Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 330:15 (1994), 1041–1046.
30. 30 Ganna, A., Magnusson, P.K., Pedersen, N.L., et al. Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol 33:9 (2013), 2267–2272.
31. 31 Joseph, P.G., Pare, G., Asma, S., Engert, J.C., Yusuf, S., Anand, S.S., INTERHEART Investigators. Impact of a genetic risk score on myocardial infarction risk across different ethnic populations. Can J Cardiol 32:12 (2016), 1440–1446.
32. 32 Purcell, S.M., Wray, N.R., Stone, J.L., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:7256 (2009), 748–752.
33. 33 Simonson, M.A., Wills, A.G., Keller, M.C., McQueen, M.B., Recent methods for polygenic analysis of genome-wide data implicate an important effect of common variants on cardiovascular disease risk. BMC Med Genet, 12, 2011, 146.
34. 34 Holmes, M.V., Asselbergs, F.W., Palmer, T.M., et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 36:9 (2015), 539–550.
35. 35 Larifla, L., Beaney, K.E., Foucan, L., et al. Influence of genetic risk factors on coronary heart disease occurrence in Afro-Caribbeans. Can J Cardiol 32:8 (2016), 978–985.
36. 36 Qi, L., Ma, J., Qi, Q., Hartiala, J., Allayee, H., Campos, H., Genetic risk score and risk of myocardial infarction in Hispanics. Circulation 123:4 (2011), 374–380.
37. 37 Yiannakouris, N., Katsoulis, M., Dilis, V., et al. Genetic predisposition to coronary heart disease and stroke using an additive genetic risk score: a population-based study in Greece. Atherosclerosis 222:1 (2012), 175–179.
38. 38 Antiochos, P., Marques-Vidal, P., McDaid, A., Waeber, G., Vollenweider, P., Association between parental history and genetic risk scores for coronary heart disease prediction: the population-based CoLaus study. Atherosclerosis 244 (2016), 59–65.
39. 39 Kullo, I.J., Jouni, H., Austin, E.E., et al. Incorporating a genetic risk score into coronary heart disease risk estimates: effect on low-density lipoprotein cholesterol levels (the MI-GENES Clinical Trial). Circulation 133:12 (2016), 1181–1188.
40. 40 Ripatti, S., Tikkanen, E., Orho-Melander, M., et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet 376:9750 (2010), 1393–1400.
41. 1 Nikpay, M., Goel, A., Won, H.H., et al. A comprehensive 1000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 47:10 (2015), 1121–1130.